Jefferies Highights Incremental Positive Feedback on Questcor's (QCOR) Acthar at Meeting

Jefferies reiterated its Buy rating and $60 price target on Questcor Pharmaceuticals (NASDAQ: QCOR) following incremental positive feedback on Acthar in DM/PM from physicians at The Myositis Association (TMA) Meeting.

The analyst comments: "Most physicians had positive views of the Levine case-study and were willing to prescribe Acthar to their salvage pts (>5th-line), which is in line w/ our expectations. The ADAPT registry is active and will collect on pt experience, which we believe will help assuage physicians concerns over the lack of data."

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $50.05 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)